| Summary: | <i>Klebsiella pneumoniae</i> is one of the important clinical organisms that causes various infectious diseases, including urinary tract infections, necrotizing pneumonia, and surgical wound infections. The increase in the incidence of multidrug-resistance <i>K. pneumoniae</i> is a major problem in public healthcare. Therefore, a novel antibacterial agent is needed to treat this pathogen. Here, we studied the in vitro and in vivo activities of a novel antibiotic LCB10-0200, a siderophore-conjugated cephalosporin, against clinical isolates of <i>K. pneumoniae</i>. In vitro susceptibility study found that LCB10-0200 showed potent antibacterial activity against <i>K. pneumoniae</i>, including the beta-lactamase producing strains. The in vivo efficacy of LCB10-0200 was examined in three different mouse infection models, including systemic, thigh, and urinary tract infections. LCB10-0200 showed more potent in vivo activity than ceftazidime in the three in vivo models against the drug-susceptible and drug-resistant <i>K. pneumoniae</i> strains. Taken together, these results show that LCB10-0200 is a potential antibacterial agent to treat infection caused by <i>K. pneumoniae</i>.
|
|---|